Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Opinion & Analysis Cassava Sciences Inc SAVA

Healthcare
Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on neuroscience. The Company's science is based on stabilizing, but not removing, a critical protein in the Alzheimer’s brain. Its scientific approach for the treatment of Alzheimer's disease seeks to simultaneously suppress both neurodegeneration and neuroinflammation. It has two biopharmaceutical assets under... see more

Opinion & Analysis (NDAQ:SAVA)

    Cassava Shares Rise on Updated Phase 2b Alzheimer's Drug Trial Data

    Streetwise Reports June 4, 2020

    Cassava Sciences' Shares Trade Up 20% on Updated Phase 2a Alzheimer's Data

    Streetwise Reports December 9, 2019

    Three shots on goal in Q4/16 for DURECT Corp.

    The Life Sciences Report September 8, 2016

    Drug pricing, presidential politics, and three biotechs with promise

    The Life Sciences Report April 13, 2016

    From acorns mighty trees can grow: Laidlaw's Jim Molloy on budding small-cap biotechs

    The Life Sciences Report March 16, 2016

    Seven biotech names on the upswing: 2016 small-cap biotech watchlist update

    The Life Sciences Report March 11, 2016